Client Charter

We are devoted to strengthening emerging pharmaceutical markets. To this end, we commit to upholding essential principles in all of our dealings with clients. Our Client Charter is our promise to you that ...

Tag Archives: South Africa

Why all the negativity around national health insurance (NHI) in South Africa? There is so much bad news such as comments by the Solidarity Research Institute that NHI will collapse the healthcare system, the Free Market Foundation believes the NHI will be a gateway for corruption, and Alex van den Heever at Wits University thinks […]

C&C at ISPOR in Glasgow C&C will be at ISPOR Glasgow in just a few weeks. Will you? We’re presenting results of our recent work for Clients in Sub-Saharan Africa and the Middle East. We put great effort into analysing new health technologies, determining their budget impact in various markets, and assessing market access opportunities. […]

Around this time last year, we published a comparative review of the Pharmacoeconomic Guidelines in South Africa (PGSA) in the Journal of Medical Economics. The paper compared the PGSA with other middle- and high-income countries and concluded that they differ in important ways. The paper has been viewed 2791 times on the C&C site by […]

South Africa’s Cabinet of Ministers recently approved a White Paper on National Health Insurance aimed at moving the policy of universal health coverage further down the road. A National Health Insurance system would result in an integrated healthcare system founded on the principles of solidarity and redistribution of healthcare resources. The basic idea is that […]

This presentation provides highlights of a recent paper published by Dr. João Carapinha on a comparative review of the Pharmacoeconomic Guidelines in South Africa with twelve other countries. An abstract and more background information on the paper is also available here.

Journal of Medical Economics Author: Dr. João L. Carapinha, Ph.D. Objective: To compare the pharmacoeconomic guidelines in South Africa (SA) with other middle- and high-income countries. Methods: A comparative review of key features of the pharmacoeconomic guidelines in SA was undertaken using the Comparative Table of Pharmacoeconomic Guidelines developed by the International Society of Pharmacoeconomics […]

We shared a post on LinkedIn on the results of a systematic review that found half of the pharmacoeconomic studies in South Africa are good quality. The purpose of the post is to extend the discussion presented by the authors and to consider the future implications for pharmacoeconomic research in South Africa and the implementation of pharmacoeconomic […]

Carapinha & Consultants partnered with eyeforpharma to bring a webinar on creating value with accessed-based marketing. The webinar was structured around 3 core questions that eyeforpharma’s Paul Simms used to facilitate the discussion. Question 1 The first question, “In order for the industry to move forward, pharma has to prioritize” generated interesting results. 69% of respondents […]

We’ve joined eyeforpharma as their Strategic Partner to bring you a free webinar: “Remove barriers to entry by embracing an access-based approach to marketing” on Tuesday 26th May 2:30-3:30 pm SAST. Pharma companies in South Africa have products with compelling economic value propositions, however reimbursement constraints have limited the up-take and patient access to new therapies. But how do we […]

China’s National Development and Reform Commission announced earlier this week it would lift medicine price restrictions on most medicines except narcotics and psychotropics. The decision will shift price-setting decisions from regulators to the market and the Commission hopes it will improve competition and result in lower medicine prices. It is still early days whether this policy […]